Research Center of Clinical Epidemiology, Peking University Third Hospital, Beijing, China.
Department of Gastroenterology, Peking University Third Hospital, Beijing, China.
Helicobacter. 2022 Oct;27(5):e12925. doi: 10.1111/hel.12925. Epub 2022 Aug 29.
Immunotherapy, especially immune checkpoint inhibitors, has been widely used in tumor therapy and have shown ideal clinical efficacy. However, some cancers still do not respond to PD-1/PD-L1 blockade therapy effectively. Helicobacter pylori infection might affect the curative effect of immunotherapy while it is rarely reported. We aimed to visualize the research hotspots and trends of H. pylori and immunotherapy using a bibliometric analysis to help understand the future development of basic and clinical research.
The relevant publications on H. pylori and immunotherapy were searched on April 20, 2022, in the Web of Science Core Collection Database (WOSCC). The document types were limited to articles and reviews. The VOSviewer 1.6.16 software was used to assess the co-authorship, co-occurrence, citation of countries, institutions, authors, journals, and hotspot keywords. The research status and trend change of H. pylori and immunotherapy were analyzed by bibliometric analysis.
A total of 95 studies authored by 561 researchers were eventually included in this study. The majority of the retrieved studies were 55 (58%) original research articles. China conducted the greatest number of studies, followed by USA and Italy. The related topics included the following three aspects: the relationship between microorganisms and cancer, the relationship between gastric cancer and immunity, and the relationship between H. pylori and immunotherapy, including purified/cloned components of H. pylori acting as efficient adjuvant to boost tumor responses and H. pylori infection which modulate host immune responses and impact on the efficacy of antitumor immunity initiated by immune checkpoint inhibitors. The timing diagram revealed that the current research hotspots focused on effects of microorganisms on immunotherapy.
The effect of H. pylori on cancer immunotherapy is getting more and more attention in these years. It still remains uncertain, and more studies are needed in the future.
免疫疗法,特别是免疫检查点抑制剂,已广泛应用于肿瘤治疗,并显示出理想的临床疗效。然而,一些癌症对 PD-1/PD-L1 阻断疗法的反应仍然不理想。幽门螺杆菌感染可能会影响免疫疗法的疗效,但很少有报道。我们旨在通过文献计量分析来可视化幽门螺杆菌和免疫疗法的研究热点和趋势,以帮助了解基础和临床研究的未来发展。
于 2022 年 4 月 20 日在 Web of Science 核心合集数据库(WOSCC)中检索有关幽门螺杆菌和免疫疗法的相关文献。文献类型限于文章和综述。使用 VOSviewer 1.6.16 软件评估国家、机构、作者、期刊的合著、共现、引文和热点关键词。通过文献计量分析分析幽门螺杆菌和免疫疗法的研究现状和趋势变化。
最终纳入了 95 项由 561 位研究人员撰写的研究。检索到的研究大多为 55 篇(58%)原始研究文章。中国开展的研究最多,其次是美国和意大利。相关主题包括以下三个方面:微生物与癌症的关系、胃癌与免疫的关系以及幽门螺杆菌与免疫疗法的关系,包括幽门螺杆菌的纯化/克隆成分作为有效的佐剂来增强肿瘤反应和幽门螺杆菌感染调节宿主免疫反应并影响免疫检查点抑制剂启动的抗肿瘤免疫的疗效。时间线图显示,目前的研究热点集中在微生物对免疫疗法的影响上。
近年来,幽门螺杆菌对癌症免疫疗法的影响越来越受到关注。但仍存在不确定性,未来还需要更多的研究。